Compare Stocks: CLLS, ALT, VALN, and STTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.28 +1.1%	$3.06	$2.56 ▼ $6.44	$637.05M	0.18	4.27 million shs	1.43 million shs
CLLS Cellectis	$1.47 +6.5%	$2.94	$1.25 ▼ $5.48	$147.50M	2.92	50,610 shs	243,059 shs
STTK Shattuck Labs	$5.88 -0.1%	$7.04	$1.70 ▼ $8.33	$590.12M	1.09	885,294 shs	188,909 shs
VALN Valneva	$6.65 +1.2%	$5.91	$4.75 ▼ $12.23	$631.02M	1.67	65,475 shs	5,672 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+0.31%	-3.28%	+8.00%	+20.00%	-10.74%
CLLS Cellectis	-14.60%	-56.07%	-55.79%	-53.86%	-56.49%
STTK Shattuck Labs	-1.51%	-7.11%	-20.43%	+18.79%	+174.77%
VALN Valneva	+0.31%	-1.65%	-6.94%	+22.12%	-26.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.28 +1.1%	$3.06	$2.56 ▼ $6.44	$637.05M	0.18	4.27 million shs	1.43 million shs
CLLS Cellectis	$1.47 +6.5%	$2.94	$1.25 ▼ $5.48	$147.50M	2.92	50,610 shs	243,059 shs
STTK Shattuck Labs	$5.88 -0.1%	$7.04	$1.70 ▼ $8.33	$590.12M	1.09	885,294 shs	188,909 shs
VALN Valneva	$6.65 +1.2%	$5.91	$4.75 ▼ $12.23	$631.02M	1.67	65,475 shs	5,672 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+0.31%	-3.28%	+8.00%	+20.00%	-10.74%
CLLS Cellectis	-14.60%	-56.07%	-55.79%	-53.86%	-56.49%
STTK Shattuck Labs	-1.51%	-7.11%	-20.43%	+18.79%	+174.77%
VALN Valneva	+0.31%	-1.65%	-6.94%	+22.12%	-26.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$14.33	337.66% Upside
CLLS Cellectis	2.29	Hold	$5.46	272.70% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	117.49% Upside
VALN Valneva	1.67	Reduce	$9.30	39.85% Upside

Current Analyst Ratings Breakdown

Latest CLLS, ALT, VALN, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight	$9.00 ➝ $1.30
9/15/2026	CLLS Cellectis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$10.00 ➝ $8.00
9/15/2026	CLLS Cellectis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
9/15/2026	CLLS Cellectis	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
9/14/2026	VALN Valneva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/11/2026	STTK Shattuck Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/11/2026	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $14.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$40K	15,926.33	N/A	N/A	$1.99 per share	1.65
CLLS Cellectis	$79.59M	1.85	N/A	N/A	$0.76 per share	1.93
STTK Shattuck Labs	$1M	589.62	N/A	N/A	$1.30 per share	4.52
VALN Valneva	$197.56M	3.19	N/A	N/A	$1.39 per share	4.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.09M	-$0.78	N/A	N/A	N/A	-214,860.98%	-31.41%	-26.96%	11/5/2026 (Estimated)
CLLS Cellectis	-$67.59M	-$0.65	N/A	N/A	N/A	-102.34%	-94.19%	-21.34%	11/13/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)
VALN Valneva	-$130.33M	-$2.11	N/A	15.11	N/A	-110.33%	-153.20%	-39.50%	11/19/2026 (Estimated)

Latest CLLS, ALT, VALN, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/11/2026	Q2 2026	ALT Altimmune	-$0.1355	-$0.12	+$0.0155	-$0.12	$0.00 million	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/7/2026	H1 2026	CLLS Cellectis	-$0.2630	-$0.22	+$0.0430	-$0.22	$11.05 million	$6.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.07	26.78	26.78
CLLS Cellectis	1.61	1.37	1.37
STTK Shattuck Labs	N/A	27.59	27.59
VALN Valneva	2.04	2.16	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CLLS Cellectis	63.90%
STTK Shattuck Labs	58.74%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	1.60%
CLLS Cellectis	16.41%
STTK Shattuck Labs	8.79%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	57	194.52 million	191.41 million	Optionable
CLLS Cellectis	229	100.34 million	83.87 million	Optionable
STTK Shattuck Labs	40	100.36 million	91.54 million	Optionable
VALN Valneva	674	94.89 million	80.74 million	Not Optionable

CLLS, ALT, VALN, and STTK Headlines

Recent News About These Companies

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

September 15 at 2:11 PM | insidermonkey.com

Valneva (NASDAQ:VALN) versus Longeveron (NASDAQ:LGVN) Head-To-Head Analysis

September 10, 2026 | americanbankingnews.com

Valneva Aktie: Umsatz bricht um 33 Prozent ein

September 9, 2026 | boerse-express.comB

Head-To-Head Comparison: Cardio Diagnostics (NASDAQ:CDIO) & Valneva (NASDAQ:VALN)

September 8, 2026 | americanbankingnews.com

Valneva Aktie: Verkauf von Nantes vereinbart

September 6, 2026 | boerse-express.comB

Valneva (NASDAQ:VALN) Trading Up 7.1% - Time to Buy?

September 2, 2026 | marketbeat.com

Valneva (NASDAQ:VALN) Shares Gap Up - Time to Buy?

September 1, 2026 | marketbeat.com

Potential Moderna-style share surge? Takeover candidates Evotec, Valneva and Vidac Pharma in focus — analysts bullish

September 1, 2026 | msn.com

Valneva's Property Sale Buys Breathing Room as Travel-Vaccine Demand Sours

August 30, 2026 | ad-hoc-news.deA

Valneva's High-Wire Act: Can Cost Cuts and a Pivotal EMA Review Bridge the Gap to 2026?

August 29, 2026 | ad-hoc-news.deA

Answers to 3 questions about a potential Lyme vaccine

August 28, 2026 | msn.com

Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile

August 24, 2026 | ad-hoc-news.deA

Valneva (NASDAQ:VALN) Shares Gap Down - Here's Why

August 24, 2026 | marketbeat.com

Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight

August 20, 2026 | ad-hoc-news.deA

Valneva (VALN) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

Research Analysts Issue Forecasts for Valneva Q3 Earnings

August 18, 2026 | marketbeat.com

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine

August 17, 2026 | pharmabiz.comP

EMA validates Pfizer and Valneva’s Lyme disease vaccine

August 17, 2026 | msn.com

Pfizer, Valneva Lyme vaccine starts review in Europe

August 15, 2026 | pharmaphorum.comP

Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance

August 15, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLLS, ALT, VALN, and STTK Company Descriptions

Altimmune NASDAQ:ALT

$3.28 +0.04 (+1.08%)

As of 12:47 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Cellectis NASDAQ:CLLS

$1.46 +0.09 (+6.55%)

As of 12:47 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Shattuck Labs NASDAQ:STTK

$5.88 -0.01 (-0.09%)

As of 12:47 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Valneva NASDAQ:VALN

$6.65 +0.08 (+1.22%)

As of 12:31 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, ALT, VALN, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, ALT, VALN, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, ALT, VALN, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLLS, ALT, VALN, and STTK Company Descriptions

Altimmune NASDAQ:ALT

Cellectis NASDAQ:CLLS

Shattuck Labs NASDAQ:STTK

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, ALT, VALN, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, ALT, VALN, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, ALT, VALN, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLLS, ALT, VALN, and STTK Company Descriptions

Altimmune NASDAQ:ALT

Cellectis NASDAQ:CLLS

Shattuck Labs NASDAQ:STTK

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools